TESARO (NASDAQ:TSRO)‘s stock had its “buy” rating reiterated by equities research analysts at Cantor Fitzgerald in a report issued on Friday. They presently have a $68.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 170.92% from the company’s previous close.
The analysts wrote, “. We reiterate our Overweight rating and 12-month price target of $68. This morning, TSRO presented an updated GARNET study (anti- PD1 TSR-042) results in 2nd line NSCLC patients and also initial safety results from the anti-LAG-3 agent TSR-033 in poster presentations at the ongoing SITC annual meeting. Overall, the GARNET data reported improved response rates in a larger cohort size of 2nd line NSCLC patients and TSR-042 activity profile in this setting looks compelling so far. The anti-LAG-3 initial safety data were largely in- line with the published abstract.””
TSRO has been the topic of a number of other research reports. BidaskClub lowered TESARO from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 25th. Cann reiterated a “buy” rating and issued a $83.00 target price on shares of TESARO in a research report on Tuesday, September 4th. Leerink Swann assumed coverage on TESARO in a research report on Monday, September 24th. They issued an “outperform” rating and a $48.00 price objective on the stock. Citigroup lowered their price objective on TESARO from $100.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, August 29th. Finally, Barclays lowered their price objective on TESARO from $60.00 to $56.00 and set an “overweight” rating on the stock in a research report on Monday, August 6th. Nine equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $73.90.
Shares of NASDAQ TSRO opened at $25.10 on Friday. TESARO has a 52 week low of $23.41 and a 52 week high of $92.71. The company has a quick ratio of 3.64, a current ratio of 3.40 and a debt-to-equity ratio of 3.74.
TESARO (NASDAQ:TSRO) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.62) by $0.13. The firm had revenue of $64.40 million for the quarter, compared to analyst estimates of $71.84 million. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. TESARO’s revenue for the quarter was down 54.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.47) earnings per share. On average, research analysts anticipate that TESARO will post -10.97 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the business. Essex Investment Management Co. LLC purchased a new position in shares of TESARO during the 2nd quarter valued at approximately $733,000. ING Groep NV purchased a new position in shares of TESARO during the 2nd quarter valued at approximately $667,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of TESARO by 49.9% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 136,441 shares of the biopharmaceutical company’s stock valued at $6,068,000 after buying an additional 45,450 shares in the last quarter. KBC Group NV lifted its position in shares of TESARO by 20.0% during the 2nd quarter. KBC Group NV now owns 10,533 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 1,752 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in shares of TESARO during the 2nd quarter valued at approximately $257,000.
TESARO Company Profile
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Further Reading: Reverse Stock Split
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.